logo
logo

Loqus23 Therapeutics Exits Stealth With £11.5 Million Seed Financing From The Dementia Discovery Fund And Novartis Venture Fund

Nov 23, 2021•over 3 years ago

Amount Raised

£11.5 Million

Round Type

seed

Cambridge

Description

LoQus23 Therapeutics Ltd. ('LoQus23'), a company discovering small molecule therapies that target aberrant DNA mismatch repair (MMR) to treat Huntington's and other triplet repeat diseases (TRDs), announces the successful closing of its £7 million extended seed round. LoQus23 secured the financing from Novartis Venture Fund (NVF) and its founding investor the Dementia Discovery Fund (DDF). This round follows an initial £4.5 million seed investment by the DDF in 2019.

Company Information

Company

Lo Qus23 Therapeutics Ltd

Location

Cambridge, Maryland, United States

About

LoQus23 is a biotech company discovering oral therapies targeting aberrant DNA mismatch repair for the treatment of Huntington's Disease and other triplet repeat disorders. Targeting DNA mismatch repair has the potential to stop DNA instability and therefore slow neurodegeneration in these diseases. LoQus23 is focused on using a structure-based approach to design small molecule drugs, which can offer more convenient administration than other approaches. LouQs23 was founded in 2019 by members of the Dementia Discovery Fund including Dr David Reynolds, Dr Caroline Benn, and Dr Ruth McKernan FMedsci CBE. The Company is headquartered in Cambridge, UK. For more information please visit www.loqus23.com

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech